Myocardial infarction, usually known as a heart attack that may be defined as the development of heart muscle necrosis results from an acute interruption of blood supply to a part of the heart.
Myocardial infarction is classified into two types;
(1) ST-segment elevation myocardial infarction (STEMI): In STEMI, cardiac muscle necrosis occurs that is demonstrated by an elevation of cardiac markers (CK-MB or Troponin) in the blood and the presence of persistent ST-segment elevation in electrocardiography.
(2) Non ST-segment elevation myocardial infarction (NSTEMI): In NSTEMI, cardiac muscle necrosis occurs that is demonstrated by an elevation of cardiac markers (CK-MB or Troponin) in the blood and the absence of persistent ST-segment elevation in electrocardiography.
Acute myocardial infarction usually occurs by developing a partial or complete occlusion of one or more of the coronary arteries previously affected by atherosclerosis. The most common cause is rupture or erosion of an atherosclerotic plaque that triggers platelet aggregation and fibrin deposition, which lead to formation of a thrombus in a coronary artery at the site of the atherosclerotic plaque. This arterial thrombus causes interruption of blood supply to part of the myocardium (heart muscle), profound changes take place in the myocardium (heart muscle) that lead to irreversible changes and death of myocardial cells, and ultimately acute myocardial infarction develops.
Clinical symptoms and signs:
- Chest pain: Chest pain is the cardinal symptom of acute myocardial infarction. Pain is constricting, dull, choking or heavy in character, usually located in the centre of the chest, but may radiate to neck, jaw, shoulder, back, and arms (most commonly left arm). Occasionally, pain may be felt only at the sites of radiation. In older patient patients or those with diabetes mellitus, painless myocardial infarction may occur.
- Difficulty in respiration: Sometimes breathing difficulty develops due to ischemic left ventricular dysfunction or dynamic mitral regurgitation.
- Nausea, vomiting, and sweating: Due to autonomic upset.
- Syncope (sudden loss of consciousness): Sometimes patients may present with syncope, usually due to an arrhythmia or severe hypotension.
- Tachycardia (high pulse rate): Due to sympathetic nerve activation.
- Bradycardia (low pulse rate): Patients with inferior myocardial infarction may present with bradycardia due to vagus nerve activation.
- Shock: Some patients may present with shock due to impaired myocardial function.
Diagnosis of myocardial infarction is done by clinical symptoms and signs with following investigations:
- Electrocardiography: ECG finding of STEMI is usually associated with ST-segment elevation, pathological Q-wave formation and T-wave inversion, and NSTEMI is usually associated with ST-segment depression, transient ST-segment elevation, or T-wave inversion.
- Cardiac markers: Cardiospecific isoenzyme CK-MB (creatine kinase myocardial band), and cardiospecific proteins troponin T and troponin I are rises in acute myocardial infarction. CK-MB starts to rise at 4-6 hours and falls to normal within 48-72 hours. Troponin T and troponin I start to rise at 4-6 hours and remain high for up to two weeks.
- Full blood count – Elevation of WBC count is usual. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) may elevate.
- Chest X-ray – Assess for signs of lung edema.
- Echocardiography – It is done for assessing ventricular function and for detecting important complications.
Early complications of myocardial infarction are as followings:
(A) Arrhythmias: Many patients with myocardial infarction may develop following form of arrhythmia:
- Ventricular fibrillation
- Ventricular tachycardia
- Ventricular ectopics
- Accelerated idioventricular rhythm
- Atrial fibrillation
- Atrial tachycardia
- Atrioventricular block
- Sinus bradicardia
In majority of cases arrhythmia is transient. Rest, pain relief and correction of hypokalaemia may prevent them.
(B) Left ventricular failure: It is due to extensive myocardial infarction.
(C) Cardiogenic shock: It is due to left ventricular dysfunction.
(D) Percarditis – pericarditis develop on the second or third days after myocardial infarction. Patient may feel a different type of pain that tends to be worse or sometimes only feel on inspiration.
(E) Embolism: On the endocardial surface of infracted heart muscle, thrombus often forms. This thrombus may lodge and lead to development of systemic embolism that occationally causes stroke or ischemic limp.
(F) Mitral regurgitation – it is due to papillary muscle infarction.
(1) Post MI syndrome (Dressler’s syndrome): It usually occurs 1-3 weeks after myocardial infarction, and is characterized by fever, pericarditis and pleuritis, and is probably due to myocardial antigens released after infarction. Management is with NSAIDs, high dose aspirin or even corticosteroids.
(2) Left ventricular aneurysm: In myocardial infarction, part of the infracted area of ventricle becomes dilate and moves paradoxically during systole. Ventricular aneurysm can be minimized by use of ACE inhibitor and beta-blocker.
Patients should be admitted immediately to hospital, preferably to a cardiac care unit because there is a significant risk of death.
(1) Bed rest with continuous monitoring by ECG.
(2) Inhaled oxygen therapy.
(3) Relief of pain by opiate analgegic: Intravenous morphine 10 mg or diamorphine 5 mg is usually used and may have to be repeated to relieve severe pain.
(4) Antiplatelet therapy: Antiplatelet drugs prevent platelet aggregation within coronary artery. A 300 mg tablet of aspirin should be given orally as early as possible then 75 mg daily should be continued indefinitely if there are no side effects occur. Aspirin reduces the mortality rate of NSTEMI by approximately 25%. In combination of aspirin, clopidogrel 600 mg should be given orally as early as possible, followed by 150 mg daily for 7 days and 75 mg daily thereafter, gives a further reduction in mortality. Ticagrelor 150 mg followed by 90 mg two times daily is more effective than clopidegrol. High risk patients, especially patients with diabetes mellitus or patients who undergo percutaneous coronary intervention (PCI), should also be considered for intake of glycoprotein IIb/IIIa receptor blocker (block the final common pathway of platelet aggregation), such as tirofiban, abciximab, or eptifibatide.
(5) Anticoagulant therapy: Anticoagulant drugs prevent reinfarction, and reduces the risk of thromboembolic complications. Anticoagulation can be achieved by using unfractionated heparin, low molecular weight heparin or fractionated heparin (enoxaparin, dalteparin), or a pentasaccharide (fondaparinux). Comparatively low molecular weight heparin is more safety and efficacious than unfractionated heparin, and pentasaccharide is more safety and efficacious than low molecular weight heparin. The dose regimens are:
- Enoxaparin: 1 mg/kg body weight two times daily usually for 8 days by subcutaneous injection.
- Dalteparin: 120 units/kg body weight two times daily usually for 8 days by subcutaneous injection.
- Fondaparinux: 2.5 mg daily usually for 8 days by subcutaneous injection.
(6) Beta-blockers: Beta-blockers reduce arrhythmias, heart rate, blood pressure and myocardial oxygen demand, and relive pain. Oral beta-blocker atenolol 25-50 mg twice daily, metoprolol 25-50 mg twice daily, or bisoprolol 5 mg once daily are usually adequate. Patients with heart rate more than 90 beats/minute or patients with hypertension (systolic blood pressure more than 150 mmHg or diastolic more than 90 mmHg), intravenous beta-blockers (atenolol 5-10 mg or metoprolol 5-15 mg over 5 minutes) can be given. Beta-blockers should be avoided if there is heart failure, heart block, hypotension, or bradycardia.
(7) Nitrates: Nitrates act as a vasodilator and relief pain. Nitrates should first be given buccally or by sublingual (under tongue) spray. If the patient experiencing persistent ischemic chest pain after 3 doses given 5 minutes apart, then intravenous glyceryl trinitrate 0.6-1.2 mg/hour or isosorbide dinitrate 1-2 mg/hour can be given until pain relieved or systolic blood pressure falls to less than 100 mgHg. Oral or sublingual nitrates can be used once the pain has resolved.
(8) Statins: Irrespective of serum cholesterol level, all patients should receive statin (atorvastatin, rosuvastatin, simvastatin etc.) after STEMI.
(9) ACE (angiotensin converting enzyme) inhibitors or ARBs (angiotensive receptor blockers): An ACE inhibitor such as ramipril, enalapril, captopril, or lisinopril is started 1 or 2 days after STEMI. ACE inhibitor therapy reduces ventricular remodeling, prevent the onset of heart failure, and reduce recurrent infarction. ARBs (valsartan, candesartan, losartan, olmesartan etc.) are suitable alternatives in patients with STEMI intolerant of ACE inhibitors.
(10) Reperfusion therapy: All patients with STEMI should be considered for primary PCI (percutaneous coronary intervention). Where PCI is not available or primary PCI cannot be achieved within 120 minutes of diagnosis, thrombolytic therapy such as alteplase, tenecteplase, reteplase,or streptokinase should be administered. On the other hand, all patients with NSTEMI should be considered for early coronary angiography and revascularization, either by PCI (percutaneous coronary intervention) or by CABG (coronary artery bypass grafting), especially where they are at medium to high risk patients. Early medical treatment is appropriate in low risk patients, and coronary angiography and revascularization reserved for those who fail to settle with medical treatment.
- Restrict physical activities for four to six weeks – Death tissue of infarct area in heart muscle takes 4-6 weeks to be replaced with fibrous tissue.
- Cessation of cigarette smoking.
- Maintaining an ideal body weight.
- Eating a Mediterranean style diet (diet rich in monounsaturated fatty acids and omega-3 fatty acids, but low in saturated fatty acids).
- Achieving well control of high pressure and diabetes mellitus.
- Taking regular exercise up to, but not beyond, the point of chest discomfort.
- Continue secondary prevention drugs therapy including aspirin, clopidogrel, beta-blocker, ACE inhibitor, and statin.